Inside information, Juho Himberg has been appointed CEO of Optomed
Optomed Plc Inside Information 3 August 2023 at 18.15, Helsinki
Inside information, Juho Himberg has been appointed CEO of Optomed
Optomed’s Board of Directors has appointed Juho Himberg as the new CEO of Optomed Plc. He will start in his position the 1st of October 2023.
Previously Juho Himberg has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative products and services for improving the well-being and quality of life for people around the world. Prior to Aidian, Juho has held several leadership positions globally in healthcare and medical technology companies such as Orton, Stryker, C.R. Bard Inc. and Gambro.
“I am very pleased with the outcome of the recruitment process, and Juho Himberg is the best possible choice for the new CEO of Optomed. Through his versatile work history, Juho has demonstrated not only an understanding of health care business areas but also having strong management and commercialization skills. We see these as the special strengths for the future of Optomed. I want warmly welcome Juho to Optomed.” Petri Salonen, Optomed chairperson comments.
“It is a pleasure and honor to become a part of Optomed´s team. Optomed has unique expertise and capabilities to create scalable solutions that can save sight of millions of people. I am eagerly looking forward to developing the company further and strengthening its position as a global player in healthcare together with Optomed´s employees. I would like to thank the Board of Directors for their trust in me." Juho Himberg says.
Optomed Plc
Further enquiries
Petri Salonen, Chairperson, tel. +358 50 594 1510, [email protected]
Optomed in Brief
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company’s products are sold via various sales channels in over 60 countries globally
